Plexxikon’s License Agreement with Novellus

Sidley represented Plexxikon.

NovellusDx, a precision-oncology drug development company, announced that it has entered into an exclusive worldwide license agreement with Plexxikon Inc., a member of the Daiichi Sankyo Group, for PLX8394, its clinical-stage oncology drug candidate which targets the BRAF protein. PLX8394 is currently completing a Phase 1/2 trial in patients with advanced, unresectable solid tumors.

Under the terms of the agreement, Plexxikon grants Novellus rights to research, develop, manufacture and exclusively commercialize PLX8394 worldwide. Plexxikon will receive an undisclosed upfront payment, additional developmental milestones, and royalty payments.

PLX8394 is an investigational, oral, small molecule inhibitor of the oncogenic BRAF serine/threonine-protein kinase, which accelerates BRAF mutant cancers by activating the RAS/MAPK pathway.

Plexxikon, member of the Daiichi Sankyo Group, is a leader in structure-guided discovery and the development of novel small molecule pharmaceuticals to treat human disease.

Novellus is a precision oncology drug development company focused on developing treatments to unique patient sub-populations.

The Sidley team included Stephen Abreu (Picture, Partner) and Longbo Wang (Associate).

Involved fees earner: Stephen Abreu – Sidley Austin LLP; Longbo Wang – Sidley Austin LLP;

Law Firms: Sidley Austin LLP;

Clients: Plexxikon Inc;


Author: Ambrogio Visconti